392 related articles for article (PubMed ID: 35693820)
1. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
2. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
3. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
4. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
5. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.
Saharinen P; Silvennoinen O
J Biol Chem; 2002 Dec; 277(49):47954-63. PubMed ID: 12351625
[TBL] [Abstract][Full Text] [Related]
6. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
7. Identification of imidazo[1,2-
Moslin R; Gardner D; Santella J; Zhang Y; Duncia JV; Liu C; Lin J; Tokarski JS; Strnad J; Pedicord D; Chen J; Blat Y; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Sack JS; Muckelbauer JK; Chang C; Tredup J; Xie D; Aranibar N; Burke JR; Carter PH; Weinstein DS
Medchemcomm; 2017 Apr; 8(4):700-712. PubMed ID: 30108788
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Chang Y; Xu S; Ding K
J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain.
Virtanen AT; Haikarainen T; Sampathkumar P; Palmroth M; Liukkonen S; Liu J; Nekhotiaeva N; Hubbard SR; Silvennoinen O
Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678572
[TBL] [Abstract][Full Text] [Related]
11. Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
Raivola J; Haikarainen T; Silvennoinen O
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31892268
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
[TBL] [Abstract][Full Text] [Related]
15. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
17. Recent progress on tyrosine kinase 2 JH2 inhibitors.
Deng L; Wan L; Liao T; Wang L; Wang J; Wu X; Shi J
Int Immunopharmacol; 2023 Aug; 121():110434. PubMed ID: 37315371
[TBL] [Abstract][Full Text] [Related]
18. Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Raivola J; Hammarén HM; Virtanen AT; Bulleeraz V; Ward AC; Silvennoinen O
Front Oncol; 2018; 8():560. PubMed ID: 30560087
[TBL] [Abstract][Full Text] [Related]
19. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
20. Identification of
Moslin R; Zhang Y; Wrobleski ST; Lin S; Mertzman M; Spergel S; Tokarski JS; Strnad J; Gillooly K; McIntyre KW; Zupa-Fernandez A; Cheng L; Sun H; Chaudhry C; Huang C; D'Arienzo C; Heimrich E; Yang X; Muckelbauer JK; Chang C; Tredup J; Mulligan D; Xie D; Aranibar N; Chiney M; Burke JR; Lombardo L; Carter PH; Weinstein DS
J Med Chem; 2019 Oct; 62(20):8953-8972. PubMed ID: 31314518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
